ENSG00000196367 |
|
esophageal adenocarcinoma |
missense_variant |
8.447% (37/438) |
1 entry |
ENSG00000196367 |
|
breast ductal adenocarcinoma |
sequence_alteration |
10.85% (65/599) |
1 entry |
ENSG00000196367 |
|
colorectal adenocarcinoma |
missense_variant |
9.841% (149/1514) |
4 entries |
ENSG00000196367 |
|
melanoma |
frameshift_variant |
18.81% (19/101) |
1 entry |
ENSG00000196367 |
|
colorectal adenocarcinoma |
stop_gained |
9.841% (149/1514) |
2 entries |
ENSG00000196367 |
|
skin melanoma |
sequence_alteration |
7.512% (77/1025) |
3 entries |
ENSG00000196367 |
|
skin melanoma |
stop_gained |
7.512% (77/1025) |
1 entry |
ENSG00000196367 |
|
esophageal adenocarcinoma |
sequence_alteration |
8.447% (37/438) |
1 entry |
ENSG00000196367 |
|
skin melanoma |
missense_variant |
7.512% (77/1025) |
8 entries |
ENSG00000196367 |
|
colorectal adenocarcinoma |
sequence_alteration |
9.841% (149/1514) |
1 entry |
ENSG00000196367 |
|
colorectal adenocarcinoma |
frameshift_variant |
9.841% (149/1514) |
2 entries |
ENSG00000196367 |
|
melanoma |
missense_variant |
18.81% (19/101) |
2 entries |
ENSG00000196367 |
|
basal cell carcinoma |
sequence_alteration |
22.41% (13/58) |
1 entry |
ENSG00000196367 |
|
basal cell carcinoma |
missense_variant |
22.41% (13/58) |
1 entry |
ENSG00000196367 |
|
bronchoalveolar adenocarcinoma |
missense_variant |
8.696% (2/23) |
1 entry |
ENSG00000196367 |
|
gastric adenocarcinoma |
missense_variant |
6.152% (43/699) |
1 entry |
ENSG00000196367 |
|
colon carcinoma |
missense_variant |
25.0% (2/8) |
1 entry |
ENSG00000196367 |
|
bladder transitional cell carcinoma |
missense_variant |
4.38% (6/137) |
1 entry |
ENSG00000196367 |
|
prostate carcinoma |
missense_variant |
4.225% (18/426) |
2 entries |
ENSG00000196367 |
|
bile duct adenocarcinoma |
missense_variant |
1.058% (2/189) |
1 entry |
ENSG00000196367 |
|
Merkel cell skin cancer |
missense_variant |
10.0% (3/30) |
2 entries |
ENSG00000196367 |
|
clear cell renal carcinoma |
missense_variant |
1.37% (17/1241) |
3 entries |
ENSG00000196367 |
|
gastric carcinoma |
missense_variant |
13.25% (11/83) |
1 entry |
ENSG00000196367 |
|
head and neck squamous cell carcinoma |
missense_variant |
0.9383% (7/746) |
2 entries |
ENSG00000196367 |
|
melanoma |
stop_gained |
18.81% (19/101) |
1 entry |
ENSG00000196367 |
|
oral squamous cell carcinoma |
missense_variant |
1.942% (4/206) |
4 entries |
ENSG00000196367 |
|
brain glioblastoma |
missense_variant |
0.7559% (7/926) |
2 entries |
ENSG00000196367 |
|
papillary thyroid carcinoma |
missense_variant |
0.5063% (2/395) |
2 entries |
ENSG00000196367 |
|
female breast carcinoma |
missense_variant |
1.873% (5/267) |
1 entry |
ENSG00000196367 |
|
prostate carcinoma |
sequence_alteration |
4.225% (18/426) |
1 entry |
ENSG00000196367 |
|
central nervous system primitive neuroectodermal neoplasm |
missense_variant |
1.126% (5/444) |
1 entry |
ENSG00000196367 |
|
cecum adenocarcinoma |
frameshift_variant |
7.634% (10/131) |
1 entry |
ENSG00000196367 |
|
follicular thyroid carcinoma |
missense_variant |
7.812% (5/64) |
1 entry |
ENSG00000196367 |
|
melanoma |
sequence_alteration |
18.81% (19/101) |
1 entry |
ENSG00000196367 |
|
pancreatic ductal adenocarcinoma |
missense_variant |
4.051% (51/1259) |
2 entries |
ENSG00000196367 |
|
skin melanoma |
frameshift_variant |
7.512% (77/1025) |
1 entry |
ENSG00000196367 |
|
lung adenocarcinoma |
sequence_alteration |
4.092% (48/1173) |
3 entries |
ENSG00000196367 |
|
colon adenocarcinoma |
stop_gained |
6.16% (47/763) |
2 entries |
ENSG00000196367 |
|
pharyngeal squamous cell carcinoma |
missense_variant |
6.452% (2/31) |
2 entries |
ENSG00000196367 |
|
cecum adenocarcinoma |
missense_variant |
7.634% (10/131) |
2 entries |
ENSG00000196367 |
|
squamous cell lung carcinoma |
missense_variant |
2.471% (19/769) |
2 entries |
ENSG00000196367 |
|
basal cell carcinoma |
stop_gained |
22.41% (13/58) |
1 entry |
ENSG00000196367 |
|
non-small cell lung carcinoma |
missense_variant |
3.774% (2/53) |
2 entries |
ENSG00000196367 |
|
lung adenocarcinoma |
stop_gained |
4.092% (48/1173) |
2 entries |
ENSG00000196367 |
|
small cell lung carcinoma |
missense_variant |
2.812% (9/320) |
3 entries |
ENSG00000196367 |
|
Thyroid Gland Undifferentiated (Anaplastic) Carcinoma |
missense_variant |
1.17% (2/171) |
1 entry |
ENSG00000196367 |
|
central nervous system primitive neuroectodermal neoplasm |
sequence_alteration |
1.126% (5/444) |
1 entry |
ENSG00000196367 |
|
diffuse large B-cell lymphoma |
missense_variant |
2.31% (7/303) |
2 entries |
ENSG00000196367 |
|
acute myeloid leukemia |
missense_variant |
1.542% (14/908) |
1 entry |
ENSG00000196367 |
|
colon adenocarcinoma |
frameshift_variant |
6.16% (47/763) |
1 entry |
ENSG00000196367 |
|
mucosal melanoma |
missense_variant |
14.29% (2/14) |
1 entry |
ENSG00000196367 |
|
clear cell renal carcinoma |
sequence_alteration |
1.37% (17/1241) |
1 entry |
ENSG00000196367 |
|
endometrial carcinoma |
missense_variant |
8.696% (2/23) |
1 entry |
ENSG00000196367 |
|
diffuse gastric adenocarcinoma |
missense_variant |
2.532% (2/79) |
2 entries |
ENSG00000196367 |
|
gastric adenocarcinoma |
sequence_alteration |
6.152% (43/699) |
1 entry |
ENSG00000196367 |
|
prostate adenocarcinoma |
sequence_alteration |
4.399% (64/1455) |
2 entries |
ENSG00000196367 |
|
esophageal squamous cell carcinoma |
missense_variant |
2.667% (18/675) |
5 entries |
ENSG00000196367 |
|
hepatocellular carcinoma |
missense_variant |
2.323% (21/904) |
1 entry |
ENSG00000196367 |
|
hairy cell leukemia |
missense_variant |
9.524% (2/21) |
1 entry |
ENSG00000196367 |
|
colon adenocarcinoma |
missense_variant |
6.16% (47/763) |
6 entries |
ENSG00000196367 |
|
colon adenocarcinoma |
sequence_alteration |
6.16% (47/763) |
3 entries |
ENSG00000196367 |
|
nasopharyngeal squamous cell carcinoma |
missense_variant |
2.395% (4/167) |
1 entry |
ENSG00000196367 |
|
breast carcinoma |
missense_variant |
1.488% (21/1411) |
2 entries |
ENSG00000196367 |
|
gastric intestinal type adenocarcinoma |
missense_variant |
8.235% (7/85) |
2 entries |
ENSG00000196367 |
|
ovarian serous adenocarcinoma |
missense_variant |
1.297% (9/694) |
3 entries |
ENSG00000196367 |
|
prostate adenocarcinoma |
missense_variant |
4.399% (64/1455) |
2 entries |
ENSG00000196367 |
|
Ampulla of Vater Carcinoma |
missense_variant |
2.03% (4/197) |
1 entry |
ENSG00000196367 |
|
rectal adenocarcinoma |
missense_variant |
2.715% (6/221) |
3 entries |
ENSG00000196367 |
|
HER2 Positive Breast Carcinoma |
missense_variant |
12.96% (14/108) |
3 entries |
ENSG00000196367 |
|
lung adenocarcinoma |
missense_variant |
4.092% (48/1173) |
7 entries |
ENSG00000196367 |
|
Central Nervous System Lymphoma |
missense_variant |
11.11% (1/9) |
1 entry |
ENSG00000196367 |
|
diffuse gastric adenocarcinoma |
sequence_alteration |
2.532% (2/79) |
1 entry |
ENSG00000196367 |
|
osteosarcoma |
missense_variant |
1.724% (2/116) |
1 entry |
ENSG00000196367 |
|
Adamantinomatous Craniopharyngioma |
stop_gained |
8.333% (1/12) |
1 entry |
ENSG00000196367 |
|
breast carcinoma |
conservative_inframe_deletion |
1.488% (21/1411) |
1 entry |
ENSG00000196367 |
|
marginal zone B-cell lymphoma |
missense_variant |
13.33% (2/15) |
1 entry |
ENSG00000196367 |
|
colonic neoplasm |
missense_variant |
6.667% (1/15) |
1 entry |
ENSG00000196367 |
|
pseudomyxoma peritonei |
missense_variant |
10.0% (1/10) |
1 entry |
ENSG00000196367 |
|
Gallbladder Adenocarcinoma |
missense_variant |
1.149% (1/87) |
1 entry |
ENSG00000196367 |
|
Thymic Squamous Cell Carcinoma |
missense_variant |
25.0% (1/4) |
1 entry |
ENSG00000196367 |
|
B-cell acute lymphoblastic leukemia |
missense_variant |
1.852% (1/54) |
1 entry |
ENSG00000196367 |
|
neoplasm |
missense_variant |
3.571% (1/28) |
1 entry |
ENSG00000196367 |
|
medulloblastoma |
missense_variant |
4.167% (1/24) |
1 entry |
ENSG00000196367 |
|
acute lymphoblastic leukemia |
stop_gained |
0.6079% (2/329) |
1 entry |
ENSG00000196367 |
|
rectal adenocarcinoma |
stop_gained |
2.715% (6/221) |
1 entry |
ENSG00000196367 |
|
Brain Stem Glioblastoma |
sequence_alteration |
1.786% (1/56) |
1 entry |
ENSG00000196367 |
|
clear cell renal carcinoma |
stop_gained |
1.37% (17/1241) |
1 entry |
ENSG00000196367 |
|
synovial sarcoma |
missense_variant |
12.5% (1/8) |
1 entry |
ENSG00000196367 |
|
marginal zone B-cell lymphoma |
sequence_alteration |
13.33% (2/15) |
1 entry |
ENSG00000196367 |
|
bladder transitional cell carcinoma |
sequence_alteration |
4.38% (6/137) |
1 entry |
ENSG00000196367 |
|
large cell lung carcinoma |
missense_variant |
4.167% (1/24) |
1 entry |
ENSG00000196367 |
|
adenosquamous lung carcinoma |
missense_variant |
9.091% (1/11) |
1 entry |
ENSG00000196367 |
|
acute lymphoblastic leukemia |
missense_variant |
0.6079% (2/329) |
1 entry |
ENSG00000196367 |
|
rectum adenoma |
missense_variant |
33.33% (1/3) |
1 entry |
ENSG00000196367 |
|
bone osteosarcoma |
sequence_alteration |
33.33% (1/3) |
1 entry |
ENSG00000196367 |
|
metaplastic breast carcinoma |
missense_variant |
3.922% (2/51) |
1 entry |
ENSG00000196367 |
|
Cortisol-Producing Adrenal Cortex Adenoma |
missense_variant |
0.8065% (1/124) |
1 entry |
ENSG00000196367 |
|
Malignant Germ Cell Tumor |
missense_variant |
100.0% (1/1) |
1 entry |
ENSG00000196367 |
|
adrenal cortex carcinoma |
missense_variant |
0.6098% (1/164) |
1 entry |
ENSG00000196367 |
|
head and neck squamous cell carcinoma |
sequence_alteration |
0.9383% (7/746) |
1 entry |
ENSG00000196367 |
|
salivary gland adenoid cystic carcinoma |
missense_variant |
1.961% (1/51) |
1 entry |
ENSG00000196367 |
|
ovarian serous adenocarcinoma |
sequence_alteration |
1.297% (9/694) |
1 entry |
ENSG00000196367 |
|
papillary renal cell carcinoma |
missense_variant |
0.2801% (1/357) |
1 entry |
ENSG00000196367 |
|
osteosarcoma |
sequence_alteration |
1.724% (2/116) |
1 entry |
ENSG00000196367 |
|
angiosarcoma |
missense_variant |
7.692% (1/13) |
1 entry |